Kite Pharma is flying high with the addition of a new member to its senior leadership team. Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of ...

Lobo, who is also an orthopaedic doctor, competed in kite surfing at the 2024 Paris Olympics. He is also a two-time Pan American Games champion. At the time of the rescue, he was busy training ...

Kite Pharma’s share price has dived after it emerged that a patient has died from cerebral oedema while being treated with its CAR-T therapy, KTE-C19. Investors were spooked by the news ...

Pensionfund DSM Netherlands’ holdings in Kite Realty Group Trust were worth $1,729,000 as of its most recent SEC filing. Several other hedge funds also recently modified their holdings of the stock.

Brazilian Bruno Lobo captured the moment while trying out a new camera off the coast of São Luís Olympic kite surfer Bruno Lobo has saved a woman who appeared to be drowning in the ocean.

Olympic kite surfer Bruno Lobo used his athletic prowess for good while rescuing a drowning woman from the ocean. Lobo was kite surfing and testing his camera off the coast of the city of São ...

A routine training session turned into a lifesaving mission when Brazilian Olympic kite surfer Bruno Lobo plucked a drowning woman from the ocean and brought her to shore. The 2024 Olympian was ...

Shoreline Biosciences plans to let go of an undisclosed number of employees tied to a cell therapy project with Gilead Sciences’ Kite Pharma, Endpoints News reported this week. While Shoreline ...

Brazilian kite surfer Bruno Lobo is not only an Olympic athlete, but he’s also a real-life hero. Lobo, 31, came to a drowning woman’s aid during a training session off the coast of São Luís ...

BRAZIL (CNN) - A woman who was pulled out to sea was saved by an Olympic kite surfer who happened to be in the right place at the right time. Olympian Bruno Lobo, 31, says he was making a practice ...

TmCD19-IL18 is under clinical development by Kite Pharma and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have a 78% phase transition ...